June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Extension of peripheral non-perfusion in retinal vein occlusion treated with intravitreal dexamethasone implant
Author Affiliations & Notes
  • Sandra Rezar
    Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria
  • Katharina Eibenberger
    Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria
  • Wolf Buehl
    Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria
  • Michael Georgopoulos
    Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria
  • Guenther Weigert
    Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria
  • Ursula Schmidt-Erfurth
    Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria
  • Stefan Sacu
    Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria
  • Footnotes
    Commercial Relationships   Sandra Rezar, None; Katharina Eibenberger, None; Wolf Buehl, None; Michael Georgopoulos, None; Guenther Weigert, None; Ursula Schmidt-Erfurth, Alcon (F), Allergan (F), Bayer (F), Boehringer (F), Novartis (F); Stefan Sacu, Allergan (F), Askin (F), Bayer (F), Novartis (F), Pharmaselekt (F)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 3671. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Sandra Rezar, Katharina Eibenberger, Wolf Buehl, Michael Georgopoulos, Guenther Weigert, Ursula Schmidt-Erfurth, Stefan Sacu; Extension of peripheral non-perfusion in retinal vein occlusion treated with intravitreal dexamethasone implant
      . Invest. Ophthalmol. Vis. Sci. 2017;58(8):3671.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate differences between eyes with ischemic and non-ischemic retinal vein occlusion (RVO) and evaluate the change of peripheral non-perfusion area (PNP) during intravitreal dexamethasone treatment.

Methods : Forty eyes of 40 consecutive patients with macular edema (ME) due to either branch- or central retinal vein occlusion (25 BRVO; 15 CRVO) were included for analysis. At baseline all patients were treated with an intravitreal dexamethasone implant (Ozurdex®) and re-treated if indicated earliest after 4 months. Ischemic RVO was defined as evidence of >10 disc diameter of PNP at baseline as seen on 200° wide-field fluorescein angiography. Eyes included for follow-up analysis were quantified manually for the total area of PNP by calculating the percentage of the total visible retina (ischemic index).

Results : Eighteen eyes showed evidence of PNP and were graded as ischemic RVO. At baseline and at final follow-up best-corrected visual acuity (BCVA) and central retinal thickness (CRT) did not differ between ischemic/non-ischemic RVO patients (61±14/65±15 letters and 536±172/531±131µm at baseline; 69±15/70±18 letters and 298±107/305±61 µm month 6). No difference regarding the time of dexamethasone re-treatment was identified between patients with ischemic/non-ischemic RVO (11/11 received re-treatment at month 4, 3/5 at month 5, 3/4 at month 6). In the ischemic RVO eyes, the mean area of PNP (ischemic index) was calculated to be 14.7% at baseline. One month after initial dexamethasone treatment the mean area of PNP was 13.7% and after three months 16.9% (p=0.8; p=0.4). After re-treatment total PNP area was 16.7% (month 6; p=0.8 in comparison to baseline). In eyes graded as non-ischemic the mean PNP area was 0.3% at baseline, 0.6% after one month, 0.6% after three months and 0.6% after six months, respectively (p>0.05). A significant negative correlation between the total area of PNP and VA was identified (p=0.03).

Conclusions : Using wide-field fluorescein angiography the ischemic index was shown to remain stable under intravitreal Ozurdex® treatment. Functional and anatomical outcomes did not differ between patients with ischemic and non-ischemic RVO.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×